Cerecor Inc (NASDAQ:CERC) saw a significant decline in short interest in the month of January. As of January 12th, there was short interest totalling 777,488 shares, a decline of 33.8% from the December 29th total of 1,174,319 shares. Based on an average daily trading volume, of 493,309 shares, the short-interest ratio is presently 1.6 days. Approximately 4.1% of the shares of the company are sold short.
Several research analysts have weighed in on the company. ValuEngine upgraded Cerecor from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. TheStreet upgraded Cerecor from an “e+” rating to a “c-” rating in a research note on Wednesday, November 8th.
In related news, Director Armistice Capital, Llc bought 35,200 shares of the stock in a transaction on Wednesday, November 22nd. The shares were bought at an average cost of $1.20 per share, for a total transaction of $42,240.00. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Armistice Capital Master Fund bought 45,200 shares of the stock in a transaction on Friday, November 24th. The stock was bought at an average price of $1.20 per share, for a total transaction of $54,240.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 90,685 shares of company stock worth $108,984. 10.70% of the stock is currently owned by corporate insiders.
An institutional investor recently bought a new position in Cerecor stock. Acadian Asset Management LLC bought a new stake in Cerecor Inc (NASDAQ:CERC) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 60,719 shares of the company’s stock, valued at approximately $194,000. Acadian Asset Management LLC owned about 0.23% of Cerecor at the end of the most recent quarter. Institutional investors own 64.27% of the company’s stock.
Cerecor (NASDAQ CERC) opened at $3.00 on Friday. Cerecor has a 12 month low of $0.34 and a 12 month high of $4.25. The firm has a market capitalization of $78.47 and a P/E ratio of 8.11.
Cerecor (NASDAQ:CERC) last announced its earnings results on Monday, November 6th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.76. Cerecor had a return on equity of 212.90% and a net margin of 51.71%. analysts expect that Cerecor will post 0.83 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Short Interest in Cerecor Inc (CERC) Declines By 33.8%” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/03/short-interest-in-cerecor-inc-cerc-declines-by-33-8.html.
Cerecor Company Profile
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.